Voyager Pharmaceutical Corp | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (26)

View All

Latest Posts

About This Stock More About This Stock
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
Article By: Benzinga
Monday, October 11, 2021 3:48 PM EDT
Toward the end of trading on Monday, the Dow traded down 0.37% to 34,617.17 while the Nasdaq fell 0.05% to 34,617.14. The S&P 500 also fell, dropping 0.26% to 4,379.88. Let's look at what has happened in the markets thus far.
In this article: PCRX, CENX, VYGR, SUPN, RFP, ADMS, FLXN, PTGX, HYLN, CIFR
Read
The Week Ahead In Biotech (May 23-29): Eton, Lantheus FDA Decisions, Adcom Test For Provention, Chiasma Data Presentation
Article By: Benzinga
Sunday, May 23, 2021 2:46 PM EDT
Biotech stocks advanced in the week ended May 21, as risk aversion forced traders to buy into defensives. As earnings news flow tapered, stocks took cues from clinical readouts.
In this article: LLY, PFE, IDRA, MRNA, VYGR, LNTH, PRVB, ETON, BNTX, PASG
Read
The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks
Article By: Benzinga
Sunday, December 27, 2020 2:36 PM EDT
Biotech stocks advanced for a fifth straight week in thin holiday trading. The gains, however, were more modest amid worries concerning the emergence of a new strain of coronavirus in the U.K.
In this article: PFE, RHHBY, INCY, VYGR, QURE, ATRA, OYST, OSMT, OCGN, VTRS
Read
The Week Ahead In Biotech: Focus On Mallinckrodt FDA Decision, Conference Presentations
Article By: Benzinga
Sunday, September 6, 2020 2:22 PM EDT
After remaining steady in the first three sessions of the week ended September 4, biotech stocks pulled back along with the broader market in a tech-induced sell-off. Barring anything COVID-19-related, the news flow was fairly light.
In this article: JNJ, RHHBY, VRNA, LGND, AMRN, VYGR, STRO, MNK, AGTC, ATRA
Read
After Former Citron Short Target AveXis Gets Bought, Analyst Asks 'who's Next'
Article By: The Fly
Monday, April 9, 2018 11:25 AM EDT
AveXis shares are surging after the gene therapy researcher announced an agreement to be acquired by Novartis for $218 per share, or $8.7billion in cash. This comes two years after Citron Research made a short call of a AveXis $5 price target.
In this article: NVS, AVXS Also: BMRN, VYGR, BLUE, ONCE, RGNX
Read
All Posts

Latest Tweets for $VYGR

No tweets yet!

PARTNER HEADLINES